BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zydus Lifesciences readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Zydus Lifesciences's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06427395-1111@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270418
DTEND;VALUE=DATE:20270419
SUMMARY:Lipaglyn (Saroglitazar): Phase 3 readout est. (NCT06427395)
DESCRIPTION:Lipaglyn (Saroglitazar)\, phase 3\, Primary Biliary Cholangitis
 .\nStudy: Open-Label Extension Study of Saroglitazar Magnesium in Particip
 ants With Primary Biliary Cholangitis\nEstimated primary completion: 18 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/saroglitaza
 r#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 427395
URL:https://assetmemo.bio/drug/saroglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608044-2380@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Balstilimab: Phase 2 readout est. (NCT05608044)
DESCRIPTION:Balstilimab\, phase 2\, Colorectal Cancer.\nStudy: A Study of B
 otensilimab and Balstilimab for the Treatment of Colorectal Cancer\nEstima
 ted primary completion: September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/balstilimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05608044
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07424677-1111@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Lipaglyn (Saroglitazar): Phase 3 readout est. (NCT07424677)
DESCRIPTION:Lipaglyn (Saroglitazar)\, phase 3\, Primary Biliary Cholangitis
 .\nStudy: Study of Saroglitazar Magnesium for PBC Patients With Incomplete
  Response or Intolerant to UDCA Therapy\nEstimated primary completion: Jul
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/saroglitazar#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0742
 4677
URL:https://assetmemo.bio/drug/saroglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216235-1111@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Lipaglyn (Saroglitazar): Phase 3 readout est. (NCT07216235)
DESCRIPTION:Lipaglyn (Saroglitazar)\, phase 3\, Primary Biliary Cholangitis
 .\nStudy: Long-Term Study to Evaluate the Safety and Efficacy in Participa
 nts With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinic
 al Outcomes\nEstimated primary completion: November 2032. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/saroglitazar#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07216235
URL:https://assetmemo.bio/drug/saroglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
